SSShu Sun

Shu Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shu Sun has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction patients

    by Alexander L. Reese-Petersen, Nicholas Willumsen, Patricia Palau, Julio Nunez, Shu Sun, Tina Manon Jensen, Bibi Kamall, Morten A. Karsdal, Federica Genovese


  • Open Access

    The efficacy of ivabradine in the treatment of acute myocardial infarction

    by Yonggeng Zhang, Shu Mm Sun, Song Mm Yi

    Background: Cardiovascular diseases have become a prominent threat to public health and quality of life. In recent years, some studies have reported that ivabradine can improve the cardiac function and prognosis of patients with acute myocardial infarction (AMI). Therefore, we perform a protocol for systematic review and meta-analysis to evaluate the efficacy of ivabradine for treating AMI. Methods: This protocol of systematic review and meta-analysis has been drafted under the guidance of the preferred reporting items for systematic reviews and meta-analyses protocols. We will search PubMed, Cochrane Library, Embase, Web of Science, and Medline databases for relevant studies. In addition, we will also collect 4 databases of China: China National Knowledge Infrastructure, China Biomedical Literature Database, China Science Journal Database, and Wan-fang Database. Risk of bias will be assessed using the Cochrane Handbook risk of bias assessment tool version (V.5.1.0). We will use STATA 16.0 software (Stata Corporation, College Station, TX) to perform data analysis. Results: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. Conclusion: We hypothesized that ivabradine can reduce the resting heart rate and improve heart function in patients with AMI.


  • Alterations in non-type I collagen biomarkers in osteogenesis imperfecta

    by Lindsey Nicol, Patrick Morar, Ying Wang, Kim Henriksen, Shu Sun, Morten Karsdal, Rosamund Smith, Sandesh C.S. Nagamani, Jay Shapiro, Brendan Lee, et al.


  • Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease

    by Natasja Stæhr Gudmann, Tina Manon-Jensen, Jannie Marie Bülow Sand, Claudia Diefenbach, Shu Sun, Annette Danielsen, Morten Asser Karsdal, Diana Julie Leeming


  • A fragment of SPARC reflecting increased collagen affinity shows pathological relevance in lung cancer – implications of a new collagen chaperone function of SPARC

    by S.N. Kehlet, T. Manon-Jensen, S. Sun, S. Brix, D.J. Leeming, M. A. Karsdal, N. Willumsen

    The matricellular protein SPARC (secreted proteome acidic and rich in cysteine) is known to bind collagens and regulate fibrillogenesis. Cleavage of SPARC at a single peptide bond, increases the affinity for collagens up to 20-fold. To investigate if this specific cleavage has pathological relevance in fibrotic disorders, we developed a competitive ELISA targeting the generated neo-epitope on the released fragment and quantified it in serum from patients with lung cancer, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and healthy subjects. Furthermore, the ability of SPARC to protect fibrillar collagens from proteolytic degradation was investigated in vitro, potentially adding a new collagen chaperone function to SPARC. The fragment was significantly elevated in lung cancer patients when compared to healthy subjects measured in a discovery cohort (p = 0.0005) and a validation cohort (p < 0.0001). No significant difference was observed for IPF and COPD patients compared to healthy subjects. When recombinant SPARC was incubated with type I or type III collagen and matrix metalloproteinase-9, collagen degradation was completely inhibited. Together, these data suggest that cleavage of SPARC at a specific site, which modulates collagen binding, is a physiological mechanism increased during pathogenesis of lung cancer. Furthermore, inhibition of fibrillar collagen degradation by SPARC adds a new chaperone function to SPARC which may play additional roles in the contribution to increased collagen deposition leading to a pro-fibrotic and tumorigenic environment.


  • Open Access

    Tumstatin, a Matrikine Derived from Collagen Type IVα3, is Elevated in Serum from Patients with Non–Small Cell Lung Cancer

    by Signe Holm Nielsen, Nicholas Willumsen, Susanne Brix, Shu Sun, Tina Manon-Jensen, Morten Karsdal, Federica Genovese


  • Open Access

    The endothelial specific isoform of type XVIII collagen correlates to annual bleeding rate in haemophilia patients

    by Nadja Gad Kjeld, Baolai Hua, Morten Asser Karsdal, Shu Sun, Tina Manon-Jensen

    The medical need in the haemophilic (HF) field to reduce bleeding incidents requires measurement of the annual bleeding rate (ABR) in haemophiliacs. Vascular rupture is associated with damage to the vascular endothelium causing exposure of the basement membrane. Endothelial cells and matrix impairment may be associated with joint bleeds and later development of HF arthropathy. Imbalanced extracellular matrix turnover is a central pathological feature in many diseases consequent to epithelial or endothelial cell damage. Type XVIII collagen is an essential basement membrane component, with an endothelial specific isoform. To quantify the basement membrane specifically for the endothelial cells, as that may have particular relevance to endothelial cell stability and rupture in haemophiliacs. A newly developed ELISA assay detecting endothelial type XVIII collagen (COL-18N) was used to assess the clinical relevance of endothelial basement membrane turnover in patients diagnosed with HF arthropathy and correlation to ABR. We developed an ELISA assay for quantification of COL-18N. Serum from 35 male HF patients was investigated using the COL-18N ELISA. COL-18N correlated to the ABR of haemophiliacs, r = 0.45, P<0.006. Vascular rupture and consequent bleeding are associated with joint damage and deterioration of life quality in haemophiliacs. Quantification of ABR is an important part in efficacy assessment of different interventions, and the benchmark of these. Objective biomarkers reflecting endothelial dysfunction, vascular leaks and rupture, like the COL-18N biomarker that associate with ABR, may assist in identifying the most optimal treatment and monitoring of HF patients.


    • 1 January 2018
      • Vol. 36  (1) , 94-101

    Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis

    by A. S. Siebuhr, C. F. Kjelgaard-Petersen, S. Sun, I. Byrjalsen, C. Christiansen, M. A. Karsdal, A. C. Bay-Jensen

    Objective Biologics for rheumatoid arthritis (RA) patients with moderate to severe disease may preserve joint function. Matrix metalloproteinase 3 (MMP-3), a key tissue degrading protease, is highly elevated in RA. MMP-3, which measures the total pool of circulating MMP-3 species (cMMP3), is a commonly measured biomarker in rheumatology. The aim was to investigate the association of activated MMP-3 (actMMP3) species with treatment response compared to cMMP-3. Methods The LITHE biomarker study (n=741) was a 1-year phase III, double-blind, placebo-controlled, parallel group study of TCZ in RA patients on stable methotrexate. cMMP-3 and actMMP-3 were assessed in fasting serum at baseline, week 4, 16, 24 and 52. Patients not achieving ACR20 remission at week 16 or 28 received rescue treatment (escapers). Spearman's correlation was analysed between biomarker baseline level or biomarker delta and clinical measures. Changes in biomarker levels were studied as a function of time and treatment. Results ActMMP-3 16-week change in treatment groups was predictive of 1-year radiographic progression; a small change in actMMP3 was equal to worsening radiographics. Baseline cMMP-3 was associated with 52-weeks' radiographic status and cMMP3 16-weeks' change was predictive of 1-year change in disease activity. ActMMP-3 was dose-dependently decreased by TCZ, and escapers decreased in actMMP-3 upon treatment. Conclusion ActMMP-3 and cMMP-3 were found to be efficacy biomarkers of TCZ and actMMP-3 were able to differentiated doses. Moreover, the suppression of actMMP3, but not cMMP3 was associated with treatment response. This study illustrates that two biomarkers of the same protein may have different predictive capacities.


  • Increased basement membrane turnover and strongly attenuated interstitial matrix turnover is a key pathological feature of haemophilia

    by T. Manon‐Jensen, B. L. Hua, E. H. N. Olsen, S. Sun, C. N. Gudme, J. Li, W. Lei, B. Vandahl, K. Roepstorff, M. Kjelgaard‐Hansen, et al.


  • Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy

    by B. Hua, E. H. N. Olsen, S. Sun, C. N. Gudme, L. Wang, B. Vandahl, K. Roepstorff, M. Kjelgaard‐Hansen, B. B. Sørensen, Y. Zhao, et al.

    Introduction: Progressive arthropathy caused by recurrent joint bleeds is a severe complication in haemophilia.Aim: We investigated whether biomarkers of cartilage and bone degradation, and inflammation were altered in haemophilia patients and whether these biomarkers could identify haemophilia patients with arthropathy.Methods: Serum from 35 haemophilia patients with varying degrees of arthropathy and 43 age‐ and gender‐matched control subjects were analysed. Biomarkers of cartilage degradation (C2M, COMP, CTX‐II, ADAMTS5), cartilage formation (PRO‐C2), bone formation (PINP), bone resorption (CTX‐I) and inflammation (hsCRP, CRPM) were measured by ELISA. Arthropathy was assessed by radiological evaluation (Pettersson score) and physical examination (Gilbert score).Results: In patients with haemophilia, cartilage degradation, measured by C2M, CTX‐II and COMP, was increased by 25% (P < 0.05) compared with control subjects. Levels of the cartilage degradation enzyme, ADAMTS5, were 10% lower in haemophilia patients (P < 0.05). Bone formation (PINP) was reduced by 25% (P < 0.05) in haemophilia patients, whereas bone resorption (CTX‐I) was increased by 30% (P < 0.001). Acute inflammation (hsCRP) was increased by 50% (P < 0.01), whereas chronic inflammation (CRPM) was decreased by 25% (P < 0.0001). The hsCRP/CRPM ratio was 60% higher (P < 0.001) in haemophilia patients relative to control subjects. A biomarker panel combining C2M, CRPM, and ADAMTS5 could distinguish haemophilia patients from control subjects with 85.3% accuracy (P < 0.0001). We found no strong correlation between biomarkers and radiological and physical examination of the joint.Conclusion: Biomarkers detect increased cartilage and bone degradation, and altered inflammatory activity in haemophilia patients with arthropathy. These biomarkers could potentially be used to identify patients with progressing joint disease.